Global sterile leadership Unither operates 8 manufacturing plants across France, USA, Brazil, and China and is described as the worldwide leader in sterile unit-doses contract manufacturing, indicating strong capacity and expertise to handle high-volume sterile production for multinational pharma clients.

Innovation driven The company employs niche technologies such as Liquid Stick-Pack, Blow Fill & Seal Sterile unit-dose, multisite preservative variants, and various packaging formats, suggesting opportunities to upsell advanced manufacturing processes and differentiated packaging solutions to current and prospective customers.

Eyes on vaccines Recent participation in World Vaccine Congress 2026 and a new collaboration initiative point to strategic interest in vaccines and biologics, signaling potential sales opportunities with vaccine developers or contract partners seeking sterile manufacturing or scaling capabilities.

Expansion momentum Announcements of facility expansions in France and Western Europe, including a new ophthalmic production facility with Théa, indicate ongoing capacity growth and potential capacity-constrained clients could be approached for long-term CMOs and joint production arrangements.

Ophthalmic focus Joint development and new ophthalmic production initiatives position Unither as a potential partner for ophthalmic drug manufacturing, offering a gateway to secure projects in eye-care therapeutics and related sterile dosage forms.